Compare Crispr Therapeutics AG (CRSP) vs Fidelity National Information Servcs Inc (FIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Fidelity National Information Servcs Inc — how do they compare? Crispr Therapeutics AG trades at $51.39 (market cap $4.97B), while Fidelity National Information Servcs Inc trades at $41.2 (market cap $20.97B). The key difference: Fidelity National Information Servcs Inc is far larger — about 4.2× Crispr Therapeutics AG's market cap, and Fidelity National Information Servcs Inc pays a 4.14% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | FIS | |
|---|---|---|
Market Cap | $4.97B | $20.97B |
Sector | Health | Technology |
52-Week High | $76.78 | $81.94 |
52-Week Low | $44.34 | $37.72 |
Enterprise Value | $3.32B | $41.37B |
Dividend Yield | — | 4.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
FIS trades at $41.93, down 0.12% on the day, with a bullish technical signal from moving averages and strong institutional support. The stock shows attractive valuation metrics with a P/E of 8.13 and P/S of 1.91, while recent earnings have generally beaten expectations. Positive news flow highlights FIS's leadership in AI-driven banking technology and cloud infrastructure, with upcoming Q2 2026 earnings on August 4, 2026, providing a near-term catalyst.
The outlook for FIS is positive given its low valuation, analyst consensus price target of $52.57 (25% upside), and strategic focus on digital banking growth. Key risks include execution challenges post-Worldpay divestiture and rising debt levels, but strong cash flow generation and dividend yield of approximately 1.05% support shareholder returns. Institutional sentiment remains bullish with 58% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →
